DGAP-News: Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER
Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic.
DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER 13.10.2021 / 08:30 The issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu(R) (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo. Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximatively 5-fold on the HER2 positive breast cancer Trastuzumab and T-DM1 resistant cell line model named JIMT-1. At concentration of 0.001 ug/ml, T-deruxtecan only induce approximatively 13% of cytotoxicity comparatively to the 5 Accum-T-deruxtecan variants that increase the cytotoxicity by 21-37%.
For further information:
13.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Defence Therapeutics Inc. |
1680 - 200 Burrard St | |
V6C3L6 Vancouver | |
Canada | |
E-mail: | [email protected] |
Internet: | https://defencetherapeutics.com |
ISIN: | CA24463V1013 |
WKN: | A3CN14 |
Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
EQS News ID: | 1240336 |
End of News | DGAP News Service |
|
1240336 13.10.2021